Senescence, a persistent form of cell-cycle arrest, is often associated with a diverse secretome, which provides complex functionality for senescent cells within the tissue microenvironment. We show that oncogene-induced senescence is accompanied by a dynamic fluctuation of NOTCH1 activity, which drives a TGF-β-rich secretome, while suppressing the senescence-associated pro-inflammatory secretome through inhibition of C/EBPβ. NOTCH1 and NOTCH1-driven TGF-β contribute to 'lateral induction of senescence' through a juxtacrine NOTCH-JAG1 pathway. In addition, NOTCH1 inhibition during senescence facilitates upregulation of pro-inflammatory cytokines, promoting lymphocyte recruitment and senescence surveillance in vivo. As enforced activation of NOTCH1 signalling confers a near mutually exclusive secretory profile compared with typical senescence, our data collectively indicate that the dynamic alteration of NOTCH1 activity during senescence dictates a functional balance between these two distinct secretomes: one representing TGF-β and the other pro-inflammatory cytokines, highlighting that NOTCH1 is a temporospatial controller of secretome composition.
Cellular senescence is an autonomous tumour suppressor mechanism, whereby various triggers drive a stable proliferative arrest. Senescence is accompanied by diverse biochemical changes including upregulation of CDK inhibitors, the accumulation of senescence-associated β-galactosidase (SA-β-gal) activity, and expression of a wide variety of secretory proteins 1, 2 . These features of senescence have been recapitulated by in vivo models, including both pathological and physiological contexts 3 . Senescent cells have profound non-autonomous functionality in the tissue microenvironment through the senescence-associated secretory phenotype (SASP) 2 . Previous studies have demonstrated heterogeneous effects of the SASP on tumorigenesis. The SASP can reinforce the senescent phenotype in both an autocrine and paracrine fashion [4] [5] [6] and activate immune clearance of senescent cells [7] [8] [9] from tissues, thereby contributing to tumour suppression. Some tumorigenic activities of the SASP have also been shown through promoting cellular growth and epithelial-mesenchymal transition in neighbouring immortalized or transformed epithelial cells 10, 11 . In addition, SASP components, among others, include inflammatory cytokines and matrix-modifying enzymes, which play key roles in the clearance of senescent or damaged cells and resolution of tissue injury, respectively. Thus, it is conceivable that both the relative and absolute expression of SASP components is dynamic and under tight regulation. However, the basis for the regulation of different SASP components or controlling the net function of the SASP is unclear.
NOTCH signalling is evolutionarily conserved and involved in a wide range of developmental and physiological processes, controlling cell-fate specification and stem cell homeostasis 12 . In addition, alterations of the NOTCH pathway have been linked to stress response and tumorigenesis, where it can be oncogenic or tumour suppressive depending on tissue and context 13 . There are four NOTCH receptors, which bind the Jagged (JAG) and Delta-like family of ligands 12 .
Upon ligand binding, the NOTCH receptors undergo a series of proteolytic cleavage events liberating the intracellular domain (ICD), which subsequently translocates to the nucleus to bind a multimolecular complex, including both the DNA-binding protein RBPJ and Mastermind-like (MAML) co-activators 12 and drive transcription of NOTCH-target genes, such as the HES/HEY family of transcription 2 fold change (RIS(d6)/growing) against negative log 10 P value (n = 4 independent experiments). Among 167 proteins differentially expressed during RIS (P < 0.05), red dots indicate 94 proteins with more than twofold change. (d) Cell surface NOTCH1 expression by flow cytometry in indicated IMR90 cells: left, ER:HRAS G12V cells with (d6) or without (growing) 4OHT (iso-IgG, isotype control IgG); centre, cells with constitutive overexpression of either HRAS G12V , E1A, or both; right, DNA-damageinduced senescence (DDIS). To establish DDIS, cells were treated with 100 µM etoposide for 2 days, followed by 5 days of incubation in drug-free medium.
factors. Importantly, NOTCH ligands are also transmembrane proteins; thus, signalling is thought to be restricted to adjacent cells through juxtacrine interaction, and the role of NOTCH in autocrine or paracrine signalling through secreted factors remains unclear.
Through a quantitative cell surface proteome of oncogene-induced senescent (OIS) cells and subsequent validation, we have identified a global upregulation of NOTCH1 that is accompanied by dynamic alteration of its downstream activity during senescence. We describe how NOTCH1 functions as a master regulator of SASP composition through a temporal and functional switch between two distinct secretomes, representing TGF-β or pro-inflammatory cytokines, in part through downregulation of C/EBPβ. We show that inhibiting Notch signalling promotes clearance of OIS cells in the liver, implying a unique therapeutic opportunity to target senescent cells through modulation of immune surveillance.
RESULTS

Plasma membrane proteome in OIS
To gain a better understanding of the phenotype of OIS cells, particularly potential mediators of non-cell-autonomous signalling, we conducted a proteomic screen of plasma membrane (PM) surface proteins using a quantitative SILAC (stable isotope labelling with amino acids in cell culture) approach 14 in IMR90 human diploid fibroblasts (HDFs) expressing oncogenic HRAS G12V in a 4-hydroxytamoxifen (4OHT)-inducible form (ER:HRAS G12V ) ( Fig. 1a and Supplementary Fig. 1a ) 15 . We identified peptides from 1,502 (d) ER:HRAS G12V IMR90 cells, expressing dnMAML1-mVenus or matched control, were incubated with or without 4OHT for three days and analysed for expression of the indicated mRNA and proteins by qRT-PCR and immunoblotting respectively; n = 5 biologically independent experiments for TGFB1 and IL1B, n = 4 biologically independent experiments for IL1A; unpaired t-test. (e) ER:HRAS G12V IMR90 cells, expressing a doxycyclineinducible N1ICD-FLAG construct (TRE-N1ICD), were analysed after 6 days of treatment with 4OHT with or without doxycycline at the indicated concentrations from d3 by qRT-PCR and immunoblotting; n = 6 biologically independent experiments for all conditions (except 4OHT/1 µM Doxy where n = 5); unpaired t-test. Values are mean ± s.e.m.; * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001. Statistics source data for a, d and e are provided in Supplementary Table 2 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 . Figure 3 NOTCH1 drives a cell-autonomous senescence with a distinct secretory profile. (a,b) ER:HRAS G12V IMR90 cells, stably expressing N1ICD-FLAG or control vector (V), were incubated with or without 4OHT for 6 days and analysed for expression of the indicated proteins by immunoblotting (a) and SA-β-gal and BrdU incorporation (b). One-way ANOVA with Dunnett's multiple comparison test; bars are means of ≥200 cells, n = 4 biologically independent experiments. * * * P ≤ 0.001 versus control cells. Scale bar, 100 µm. (c) Time series analysis of the indicated transcripts after doxycycline (Doxy) induction in TRE-N1ICD-FLAG IMR90 cells by qRT-PCR. Values are mean ± s.e.m., n = 3 biologically independent experiments. Inset, immunoblotting of fractionated chromatin in IMR90 cells expressing HRAS G12V (d6) or TRE-N1ICD-FLAG (d3) for the downstream TGF-β phosphorylation target SMAD3 (phos-SMAD3). (d) TRE-N1ICD-mVenus IMR90 cells with or without 3 days of doxycycline were analysed for cell surface expression of the TGFB1 gene product latency-associated peptide by flow cytometry. (e) Differentially expressed transcripts in N1ICD-, HRAS G12V -or etoposide-induced senescent IMR90 cells (NIS, RIS or DDIS, respectively), compared with normal control cells. The heat map shows z-score-normalized fold changes of 1,150 secretome genes differentially expressed in at least in one comparison. Representative KEGG pathways enriched in four clusters (false discovery rate < 0.01) are shown. (f) TRE-N1ICD-FLAG IMR90 cells treated with or without doxycycline for three days with or without TGF-β receptor antagonists (no. 1, SB431542; no. 2, A83-01) were analysed by qRT-PCR and immunoblotting for the indicated mRNA and proteins in addition to proliferation and cell-cycle analyses. Values are mean ± s.e.m., n = 5 biologically independent experiments for CDKN2B; n = 4 biologically independent experiments for TGFB-induced (TGFBI). Statistics source data for b, c and f are provided in Supplementary  Table 2 . Unprocessed original scans of blots are shown in Supplementary  Fig. 9 .
To validate our proteomic findings, we compared the RISassociated PM changes with transcriptomic data and identified a significant positive correlation between messenger RNA and protein changes during RIS ( Supplementary Fig. 1b ).
NOTCH1 is upregulated in OIS
To understand signalling networks involving senescence-associated PM proteins, we conducted network enrichment analysis, using both transcriptomic and proteomic data. The highest enriched network contained the NOTCH1 receptor as a major network hub and its canonical targets (HES1, HEY1, and HEYL) and binding partners (RBPJ and MAML3) ( Fig. 1c and Supplementary Fig. 1c) .
Using flow cytometry, we confirmed the substantial upregulation of cell surface NOTCH1 during senescence induced by different triggers (oncogenic MEK or DNA damage) or RIS in different HDFs ( Fig. 1d and Supplementary Fig. 1d,e) . In contrast, bypass of RIS through coexpression of the adenoviral oncoprotein E1A failed to upregulate cell surface NOTCH1 on IMR90 cells (Fig. 1d) . Although the NOTCH pathway has recently been implicated in senescence [16] [17] [18] , its functional relevance is unclear.
NOTCH1 signalling is dynamically regulated during senescence
We next investigated the temporal changes of cell surface NOTCH1 and its downstream activity after ER:HRAS G12V induction. In this system, senescence develops progressively from an initial mitotic phase (∼d1) to senescence establishment (∼d6) ( Supplementary Fig. 1a ) 15 . After a slight reduction at the mitotic phase, cell surface NOTCH1 continually increased during RIS (Fig. 2a) . However, the cleaved, active NOTCH1 intracellular domain (N1ICD) and the canonical NOTCH1-target HES1 were transiently upregulated during the transition to senescence, but returned to near basal level at full senescence (Fig. 2b) . The transient activation of NOTCH1 signalling, despite increased cell surface NOTCH1, was also observed during DNA damage-induced senescence 19 (DDIS; Figs 1d right and 2c). Characterized SASP components include multiple proinflammatory cytokines, such as IL-1, IL-6 and IL-8 6, 11, 20, 21 . More recently, TGF-β ligands have been identified as SASP components, which are involved in senescence induction, in part through inducing p15 and p21 4, 5 . IL-6 and IL-8 were primarily upregulated at full senescence. However, we found a transient induction of TGF-β ligands during both RIS and DDIS, reminiscent of the N1ICD expression pattern (Fig. 2b,c and Supplementary Fig. 2a ), suggesting that NOTCH signalling temporally correlates with the reciprocal induction of TGF-β and pro-inflammatory cytokines during senescence.
NOTCH1 reciprocally regulates TGF-β and pro-inflammatory cytokines
To examine the relationship between NOTCH1 and regulation of secretory factors during RIS, we first introduced a dominant negative form of MAML1, fused to mVenus (dnMAML1-mVenus), into ER:RAS G12V -expressing IMR90 cells. At d3 after ER:RAS G12V induction, expression of dnMAML1 had minimal effect on proliferation, but completely blocked the induction of HES1 (Fig. 2d ). This inhibition of NOTCH signalling significantly reduced the upregulation of TGFB1, suggesting that NOTCH is upstream of HRAS G12V -driven TGF-β induction (Fig. 2d) . Conversely, upregulation of pro-inflammatory cytokines (IL-8, IL1A and IL1B) was enhanced by dnMAML1, suggesting that activated NOTCH1, during senescence transition, negatively regulates the expression of pro-inflammatory cytokines. Similar results were obtained pharmacologically with DAPT, a gamma secretase inhibitor, which blocks cleavage and release of the N1ICD (Supplementary Fig. 2b) . Notably, the endogenous levels of N1ICD were modestly increased in the presence of dnMAML1 regardless of induction of HRAS G12V (Fig. 2d) . This is consistent with previous studies showing that N1ICD levels are controlled by negative feedback through MAML-dependent proteasomal degradation, providing a potential mechanism for the decoupling of surface NOTCH1 and N1ICD levels 22 . We next introduced a doxycycline-inducible N1ICD-FLAG system into IMR90 cells (Supplementary Fig. 2c ). Restoration of N1ICD at the late phase of RIS (d6) led to a dose-dependent decrease in IL1A, IL1B and IL-8 expression and a dose-dependent increase in TGFB1 expression, with minimal impact on senescence arrest (Fig. 2e) . Therefore, during RIS, the dynamic alteration of NOTCH1 controls the temporally reciprocal pattern of TGF-β1 and pro-inflammatory cytokines and manipulating NOTCH signalling allows for SASP modulation with senescence arrest being maintained.
Enforced activation of NOTCH1 induces a unique senescence phenotype in HDFs
Consistent with recent reports [16] [17] [18] , expression of ectopic N1ICD drove a senescence-like morphological change with stable cell-cycle arrest, although accumulation of SA-β-gal activity was relatively modest (Fig. 3a,b and Supplementary Fig. 2d,e) . Note, proliferative arrest was maintained even after removal of ectopic N1ICD, the hallmark of senescence (Supplementary Fig. 2e ). Overexpression of N1ICD was sufficient for reduction of basal IL-8 levels as well as induction of TGF-β1 and its downstream effector phosphorylated SMAD3 (Fig. 3a,c,d ). Thus, ectopic N1ICD induces senescence that is distinct from RIS or DDIS, particularly in its SASP composition.
To understand the broader implications of NOTCH1 in the control of secretome composition, we performed mRNA-seq analysis of senescent IMR90 cells driven by HRAS G12V , DNA damage or N1ICD. Transcriptional profiling of secretory factors of RIS and DDIS shared large clusters (Fig. 3e) . Gene set enrichment analysis (GSEA) showed that all types of senescence shared a common cellcycle signature (Supplementary Fig. 3a) . However, the secretome expression profile of N1ICD-induced senescence (NIS) exhibited an almost mutually exclusive pattern with RIS and DDIS, particularly in those shared clusters (Fig. 3e) . Many secretory factors that have been associated with RIS or DDIS, such as pro-inflammatory cytokines and matrix metalloproteinases (MMP1/3/10), were repressed by ectopic N1ICD. Downregulated secretory factors at d6 of RIS, including TGF-β ligands (TGFB1/2/3), were upregulated by ectopic N1ICD in IMR90 cells. GSEA revealed a close association of TGF-β1 signatures with NIS ( Supplementary Fig. 3b ). To understand the relative dominance of RAS and N1ICD upon the secretome composition we analysed secretome transcriptional data from IMR90 cells undergoing RIS, NIS or expressing both RAS and N1ICD (N+RIS). Unsupervised clustering revealed the similarity between NIS and N+RIS secretomes, where ectopic N1ICD mostly overcame the RIS Relative expression
Vehc Doxy * * * * * * * * * * * * * * * * * * * * * * * * * * * pattern ( Supplementary Fig. 3c ). Interestingly, such dominance of NOTCH over RAS also applied to GLB1, encoding the lysosomal enzyme responsible for SA-β-Gal activity 23 , potentially explaining the modest SA-β-Gal activity of NIS (Fig. 3b) . Altogether, our data suggest that NIS and RIS are associated with reciprocal secretory profiles, and that dynamic NOTCH1 activity during senescence determines the balance between two extremities: one representing TGF-β ligands and the other representing 'classical' SASP components including proinflammatory cytokines.
NOTCH1-driven cell-autonomous senescence is partly dependent on TGF-β signalling
To understand how N1ICD induces senescence, we expressed N1ICD in the presence or absence of inhibitors of the TGF-β receptor (TGFBR1). Inhibition of TGF-β signalling prevented upregulation of TGF-β targets, CDKN2B (also known as p15) and TGFBinduced (TGFBI ), in N1ICD-expressing cells, and partly rescued the anti-proliferative effect of N1ICD ( Fig. 3f and Supplementary  Fig. 4a , left). Similar results were also obtained by expression of a dominant negative form of SMAD4 (dnSMAD4; Supplementary  Fig. 4b , left) 24 . Importantly, recombinant TGF-βs alone had no anti-proliferative effect on IMR90 cells ( Supplementary Fig. 4c,d ), suggesting that NOTCH-driven TGF-β signalling contributes to senescence cooperatively with other NOTCH1-downstream factor(s), as yet to be elucidated.
Non-cell-autonomous effects of NOTCH1 on normal cells
To investigate the non-cell-autonomous effects of differing forms of senescence, we set up co-culture experiments of mRFP-labelled, otherwise normal, IMR90 cells with senescent IMR90 cells induced by N1ICD, HRAS G12V or DNA damage. To avoid confounding effects of the 'TGF-β phase' of SASP during RIS and DDIS, senescence was preinduced for 4 days before co-culture. We found that mRFP-labelled cells co-cultured with NIS, but not late phase RIS or DDIS cells, at least in IMR90 cells, underwent a growth arrest, suggesting a key role for the NOTCH1-driven secretome in the transmission of senescence (Fig. 4a) .
To understand signalling pathways that might underpin N1ICD-mediated non-autonomous growth arrest, we co-cultured NIS and mRFP-labelled IMR90 cells for 72 h before flow sorting and then analysing gene expression in both cell populations. Consistent with N1ICD-mediated induction of TGF-β ligands in the monoculture experiments ( Fig. 3c-e) , both N1ICD-expressing and mRFP-labelled cells exhibited upregulation of the TGF-β targets CDKN2B (p15) and TGFBI (Fig. 4b) . Similarly to autonomous NOTCH1 activation, TGFBR1 inhibitors or dnSMAD4 partially rescued the nonautonomous growth arrest in mRFP-labelled cells when co-cultured with N1ICD-expressing cells ( Fig. 4c and Supplementary Fig. 4a,b) .
To further examine whether N1ICD-expressing cells induce senescence in neighbouring cells, we took advantage of the difference in the drug selection markers of retroviral vectors expressing either N1ICD (or control vector) or mRFP: after co-culturing N1ICD-expressing cells (hygromycin-resistant) and mRFP-labelled cells (puromycin-resistant), cells were incubated with puromycin for 2 days to remove N1ICD-expressing cells (Fig. 4d) . After additional culture for 5 days, mRFP-labelled cells that had been co-cultured with N1ICD-expressing cells, but not with vector-expressing cells, exhibited a senescent phenotype (Fig. 4d,e) . Importantly, this phenotype was maintained even after the removal of the signal-sending cells, indicating that the N1ICD-expressing cells transmitted a senescent phenotype to the neighbouring cells.
N1ICD-induced 'lateral induction' of senescence
The role of NOTCH in biological patterning during development is attributed to processes termed 'lateral inhibition' and 'lateral induction' 25 : NOTCH-mediated downregulation of NOTCH ligands in the same cells will negatively regulate NOTCH signalling in neighbouring cells (lateral inhibition), whereas NOTCH-mediated upregulation of NOTCH ligands will positively regulate NOTCH activity in neighbouring cells (lateral induction) 26 . Interestingly, activation of downstream NOTCH signalling was observed not only in the N1ICD-expressing cells, but also in the cocultured target cells with increased expression of HES1 (Fig. 4b ). In addition, basal levels of IL1A were repressed in both cell populations ( Fig. 4b ), suggesting that NOTCH signalling was transmitted from N1ICD-expressing cells to neighbouring cells. Among the five canonical NOTCH ligands 12 , we found a strong, unique upregulation of JAG1 after ectopic N1ICD expression ( Fig. 5a and Supplementary  Fig. 5a ). Although shedding of the extracellular domain of JAG1 has been reported, we did not detect this in conditioned media from NIS cells 27 ( Supplementary Fig. 5b ). Induction of JAG1 was also observed during the transition to RIS with up-and subsequent downregulation mirroring the dynamic expression of N1ICD ( Supplementary Fig. 2a ). Induction of senescence with increased JAG1 was confirmed in N1ICD-expressing hTERT-RPE1 cells ( Supplementary Fig. 5c ). These results suggest that N1ICD activation induces a cell-contact-dependent growth arrest through a process similar to embryonic lateral induction. To further corroborate this, we examined how downstream inhibition of NOTCH signalling in the mRFP-labelled target cells affected non-cell-autonomous suppression of proliferation in the co-culture system. Consistent with our hypothesis, use of DAPT led to a dose-dependent inhibition of the non-cell-autonomous growth arrest of mRFP-labelled cells cocultured with N1ICD-expressing cells ( Fig. 5b and Supplementary  Fig. 5d ). As expected, it had no effect on autonomous cell growth in cells expressing N1ICD, which acts downstream of gamma secretase activity (Fig. 5c ). More specifically, dnMAML1-mediated inhibition of NOTCH signalling only in the mRFP-labelled target cells also led to resistance to the non-cell-autonomous growth arrest in the co-culture system (Fig. 5d) .
We next inhibited NOTCH ligand activity in N1ICD-expressing cells. RNA-interference-mediated knockdown of JAG1 in the N1ICD-expressing IMR90 cells had no effect on cell-autonomous growth of these cells (Fig. 5e,f) , but led to a dose-dependent inhibition of the non-cell-autonomous growth arrest in the co-cultured mRFPlabelled cells ( Fig. 5g and Supplementary Fig. 5d ). Culturing the N1ICD-and mRFP-labelled cells apart using a Transwell chamber led to only a marginal decrease in proliferation of the mRFP-labelled cells (Fig. 5h) , supporting the critical role for cell-cell contact in activation of NOTCH signalling and subsequent senescence induction in cells adjacent to N1ICD-expressing cells. Similar NOTCH-mediated senescence transmission was also observed in mRFP-labelled IMR90 G12V and TRE-N1ICD with or without 4OHT (d6) and/or doxycycline (d3) (left; n = 3 biologically independent replicates or conditioned media from ER:HRAS G12V IMR90 cells, expressing dnMAML1-mVenus or matched control and incubated with or without 4OHT for 3 days (right; n = 3 biologically independent replicates) (see Supplementary  Fig. 7a ,b). Representative images (bottom) demonstrating adherent PBLs (arrows) to HSECs after pre-incubation with the indicated conditioned media. One-way ANOVA with Dunnett's multiple comparison test; bars are mean; * P ≤ 0.05, * * P ≤ 0.01. Scale bar, 50 µm. Statistics source data for a,c-e are provided in Supplementary Table 2 . Figure 7 Co-expression of NRAS G12V and N1ICD drives short-term apoptosis and long-term tumorigenesis in the liver. (a-c) Livers from mice injected with either NRAS G12V or NRAS G12V -IRES-N1ICD were subjected to immunohistochemistry for NRAS and cleaved caspase 3 staining at the indicated time points in serial sections. Relatively fewer NRAS-positive hepatocytes were detected in the NRAS G12V -IRES-N1ICD cohort (a), and these NRAS-positive cells were mostly positive for cleaved caspase 3 (d6) (b,c). Insets are magnified pictures of the dashed areas (b). Bars are means from automated image analysis of ≥10 5 cells from each liver section; d6 NRAS G12V n = 4 mice; d12 NRAS G12V n = 6 mice; d6 NRAS G12V -IRES-N1ICD n = 4 mice; d12 NRAS G12V -IRES-N1ICD n = 7 mice; unpaired t-test. Scale bar, 200 µm. (d) Mice injected with NRAS G12V (n = 7 mice) or NRAS G12V -IRES-N1ICD (n = 9 mice) underwent long-term follow-up; necropsy was performed in all to confirm the presence of liver tumours. Kaplan-Meier plots of cancer-free survival from the two cohorts; survival analysis by logrank test. (e) Example images of gross liver pathology at two months post-HDTV injection of one mouse from each cohort revealing a large tumour (arrow) and multiple small cystic lesions in the liver injected with NRAS G12V -IRES-N1ICD. (f,g) Immunohistochemical and haematoxylin and eosin (H&E) staining of serial liver sections from each cohort for the indicated proteins. H&E staining demonstrating tumour (T) infiltrating the surrounding normal parenchyma (N) and strong tumoral immunohistochemical staining for the proliferative marker Ki-67 in serial sections (g). Images in g are magnified views of the dashed areas in f. * P ≤ 0.05. Scale bar, upper panels, 5 mm; lower panels, 200 µm. Statistics source data for a and c are provided in Supplementary Table 2. cells co-cultured with N1ICD-expressing RPE1 cells, where JAG1 was upregulated ( Supplementary Fig. 5c ,e). Although it is known that TGF-β signalling can induce JAG1 expression 28 , neither TGFBR1 inhibitors or expression of dnSMAD4 affected the N1ICD-mediated upregulation of JAG1 in HDFs (Fig. 5i) , reinforcing that NOTCH is an upstream regulator of TGF-β. Together, these data indicate that N1ICD expression leads to cell-autonomous upregulation of both JAG1 and TGF-β ligands; the former triggers lateral induction of NOTCH signalling, and together with TGF-β signalling, induces senescence in neighbouring cells (Supplementary Fig. 5f ). Interestingly, the NOTCH-mediated transmission of senescence was blocked by coexisting RIS cells, which were expressing dnMAML1 to minimize the inhibitory effect of NOTCH on the 'RIS-secretome' , highlighting the functional distinction between non-autonomous activities of the two phases of RIS. This might also be involved in the negative feedback of NOTCH activity observed in the late phase of RIS in culture (Supplementary Fig. 5g ).
NOTCH1 activation during OIS in vivo
To test whether Notch signalling is involved in senescence in vivo, we first examined Kras G12D -driven pancreatic intraepithelial neoplasia (PanIN) in Kras LSL−G12D ; p48-cre mice, previously demonstrated to show evidence of senescence 29 . It was shown that Hes1 is upregulated in Kras G12D -driven mouse PanIN [30] [31] [32] . While most cells in adult wildtype pancreas exhibited low levels of Notch1 ( Supplementary Fig. 6a ), Notch1 was highly upregulated in PanIN cells that were positive for the senescence marker Dec1 29 , although the nuclear staining of Notch1 appeared heterogeneous ( Supplementary Fig. 6a ). Notch1 was also upregulated in acinar to ductal metaplasia, a potential histological precursor for PanIN, previously linked to senescence 33 ( Supplementary Fig. 6a ).
Non-cell-autonomous effects of NOTCH1 on immune clearance of senescent cells
We also examined the level of Notch1 in a mouse liver OIS model, in which transposable elements containing oncogenic NRAS G12V are stably transduced to hepatocytes through the hydrodynamic tail-vein injection (HDTV): it was shown that NRAS G12V -driven senescent hepatocytes are often surrounded by immune cells, and progressively cleared by a CD4+ T-cell-dependent immune reaction 8 . We found that cellular levels of Notch1 were upregulated in hepatocytes expressing NRAS G12V , but not in hepatocytes expressing the non-functional NRAS G12V/D38A (Fig. 6a ). To test whether Notch inhibition during NRAS G12V -driven hepatocyte senescence would modulate immune-mediated clearance of these cells, we compared two cohorts of mice, injected with NRAS G12V or NRAS G12V combined with dnMAML1. Consistent with previous reports 8 , we observed a time-dependent clearance of NRAS G12V -induced senescent hepatocytes (Fig. 6b,c) . In the presence of Notch inhibition, this clearance was accelerated with a reduction in NRAS G12V -and p21-expressing hepatocytes at d12 post-HDTV (Fig. 6b,c) . Strikingly, in NRAS G12V -expressing hepatocytes, the frequency of nuclear Hes1-positive cells progressively increased over time (Fig. 6d and Supplementary Fig. 6b) , while, at d12 when most NRAS G12V -expressing hepatocytes had been eliminated, the frequency was more variable between mice. Thus, the dynamic regulation of Notch activity observed during in vitro OIS and DDS (Fig. 2b,c) was recapitulated in vivo. Moreover, NRAS-expressing hepatocytes were often associated with neighbouring Hes1-or p21-expressing hepatocytes that did not express NRAS, at least at d9 (Fig. 6d and Supplementary Fig. 6c,d ), providing in vivo evidence for senescence-associated lateral induction of Notch signalling. Note, we failed to observe any inhibition of NRAS G12V -driven senescence (probed by p21) by dnMAML1, particularly up to d9, in both NRAS-positive and -negative hepatocytes ( Fig. 6c and Supplementary Fig. 6e ): we speculate that dnMAML1 is likely to inhibit juxtacrine-mediated, but not paracrine-mediated [4] [5] [6] or cell-autonomous, senescence. These data reinforce the immunemodulating function of Notch expression.
We confirmed the recruitment of immune cells into the liver injected with NRAS G12V ; recruitment of CD3+ T-lymphocytes, but not B220+ B-lymphocytes, was significantly accelerated in livers injected with NRAS G12V -IRES-dnMAML1 when compared with animals injected with NRAS G12V -IRES-mVenus ( Fig. 6c and Supplementary  Fig. 6f,g ).
Leukocyte recruitment to the liver requires a leukocyte adhesion cascade to sinusoidal endothelial cells, which separate the liver parenchyma from sinusoidal blood flow 34 . To examine the effect of NOTCH1-modulated secretomes on lymphocyte recruitment, we performed an in vitro flow adhesion assay 35 : human sinusoidal endothelial cells (HSECs), derived from explanted livers, were incubated in differentially conditioned media from IMR90 cells, before analysis of the ability of peripheral blood lymphocytes (PBLs) from healthy volunteers to adhere to HSECs under conditions of shear stress, recapitulating the physiological context of liver sinusoids ( Supplementary Fig. 7a,b) . Conditioned media from late phase (d6) of RIS IMR90 cells led to a significant increase in PBL adherence to HSECs and this effect was abrogated by co-expression of N1ICD (Fig. 6e) . Similarly, inhibition of the NOTCH-regulated secretome at RIS transition (d3) led to significant increases in PBL adherence to HSEC when compared with HRAS G12V -conditioned medium (Fig. 6e) . Therefore, RIS-driven secreted factor(s) act upon HSECs to facilitate lymphocyte adhesion, which is negatively regulated by NOTCH through modulation of the SASP.
We next injected NRAS G12V or NRAS G12V -IRES-N1ICD into mice; surprisingly, the number of NRAS-positive hepatocytes was much lower in the presence of ectopic N1ICD even at d6 (Fig. 7a) . To understand potential reasons for this, we stained the livers for cleaved caspase 3 (CC3), an apoptosis marker, and found that hepatocytes expressing NRAS G12V -IRES-N1ICD were often CC3-positive (Fig. 7b,c) . Nevertheless, in longer-term cohorts, most NRAS G12V -IRES-N1ICD-, but no NRAS G12V -, injected mice developed liver tumours (Fig. 7d-f) . Thus, despite the efficient induction of apoptosis, ectopic NRAS G12V and N1ICD cooperate to drive tumorigenesis. It remains to be elucidated whether this tumour formation is due to escape from senescence arrest and/or senescence surveillance, but the results underscore the contextdependent interaction between RAS and NOTCH signalling during tumorigenesis.
Our data collectively suggest that, at the endogenous level, Notch signalling modulates SASP composition in senescent hepatocytes, controlling the immune reaction in the liver and thereby negatively regulating the elimination of senescent hepatocytes, at least in part through suppressing T-lymphocyte recruitment to the liver. NF-κB and C/EBPβ, previously shown to cooperatively regulate the SASP 6, 21, 36 . NF-κB activation is primarily regulated through nuclear translocation, and consistent with previous studies 20, 36 , the level of chromatin-bound RELA/p65, the major component of NF-κB, was increased in RIS cells with its level in whole-cell lysates being unchanged (Fig. 8a) . In contrast, C/EBPβ was upregulated in both whole-cell and chromatin fractions during RIS (Fig. 8a ) 6, 21, 36 . Strikingly, ectopic N1ICD expression diminished levels of C/EBPβ, but not RELA, in both whole and chromatin fractions in RIS cells (Fig. 8a, compare lanes 2 and 4) , although ectopic N1ICD appeared to be sufficient to inhibit the basal level of chromatin-bound RELA (Fig. 8a, compare lanes 1 and 3, Supplementary Fig. 8a ).
In addition, N1ICD-mediated repression of C/EBPβ was abrogated in the presence of dnMAML1 (Fig. 8b) . GSEA revealed enrichment of a C/EBPβ signature 37 in NIS-or N+RIS-downregulated genes, and RIS-upregulated genes ( Supplementary Fig. 8b) , suggesting that the transcriptional activity of C/EBPβ is broadly diminished in N1ICD-expressing IMR90 cells.
CEBPB translates from different in-frame start sites generating two transcriptional activators, LAP * and LAP (liver-activating protein), and an amino-terminally truncated transcriptional inhibitor, LIP (liver inhibitory protein) 6 . We introduced full-length CEBPB complementary DNA (LAP * , see Methods) 6 to inducible N1ICD-expressing IMR90 cells. The enforced expression of LAP * in N1ICD-expressing cells fully restored expression of IL-8 (Fig. 8c, compare  lanes 2 and 4) and IL1A (Fig. 8d) , suggesting that repression of proinflammatory cytokines by N1ICD is primarily mediated by inhibition of C/EBPβ, although we do not exclude a role for N1ICD in qualitative regulation of the NF-κB pathway.
The preferential downregulation of C/EBPβ was also observed when IMR90 cells were treated with recombinant TNF (also known as TNFα). Ectopic N1ICD, which inhibited TNF-mediated proinflammatory cytokine induction, had no effect on the level of TNF-activated RELA (Fig. 8e) or other NF-κB family components ( Supplementary Fig. 8c ), whereas N1ICD efficiently downregulated C/EBPβ in both basal and TNF-treated conditions. Further, ectopic N1ICD-driven downregulation of C/EBPβ was also observed in the HaCaT cells, where N1ICD failed to induce senescence, suggesting that NOTCH1-mediated C/EBPβ inhibition is not limited to senescence (Supplementary Fig. 8d ).
It is well established that IL-1α acutely activates NF-κB and C/EBPβ to induce their targets, including IL1B, IL6 and IL8
38
. In the context of senescence, it was shown that IL-1α is an upstream SASP effector, regulating a cytokine network through NF-κB and C/EBPβ 21 . Thus, it is possible that N1ICD negatively regulates IL-1α and thereby C/EBPβ. However, overexpression of C/EBPβ was sufficient for inducing IL1A even in the presence of ectopic N1ICD (Fig. 8d) . In addition, when we treated N1ICD-expressing cells with recombinant IL-1α, we observed only a modest increase of C/EBPβ levels, whereas IL-6 was strongly upregulated to a level higher than control cells (Fig. 8f) , suggesting that IL-1α, like IL-1β/6/8, is also downstream of C/EBPβ. Unlike IL1B/6/8, the transcriptional regulation of IL1A is unclear. To test whether C/EBPβ directly regulates IL1A expression during senescence, we first characterized the basal profile of C/EBPβ-binding sites along with key epigenetic marks in IMR90 cells using external data sets 39, 40 . We found several C/EBPβ peaks around the IL1A locus, including a modest 'proximal' C/EBPβ peak at the transcriptional start site and a prominent 'distal' site ∼8kb upstream of the transcriptional start site (Supplementary Fig. 8e ). The proximal and distal sites were enriched for promoter and enhancer markers, respectively ( Supplementary Fig. 8e ). Interestingly, these two sites were recently identified as a promoter-enhancer pair, forming a looping interaction 41 , suggesting that this distal site is an enhancer for IL1A. Next, we performed C/EBPβ ChIP-qPCR, targeting these two regulatory regions of IL1A, as well as known C/EBPβ-binding sites at the IL6/8 loci in IMR90 cells expressing N1ICD, HRAS G12V , or both. Consistent with previous reports 6 , C/EBPβ promoter binding at the IL6/8 loci was increased in RIS cells (Supplementary Fig. 8f) . Similarly, we found that C/EBPβ binding at promoter and, more prominently, enhancer regions of IL1A was also increased (Fig. 8g) , reinforcing that IL1A is a direct C/EBPβ target. In addition, coexpression of N1ICD resulted in reduced enrichment of C/EBPβ at these regulatory regions in the context of HRAS G12V (Fig. 8g) . We propose that NOTCH1 inhibits pro-inflammatory cytokines, including IL-1α, primarily through repression of their C/EBPβ-mediated transcription (Fig. 8h) .
DISCUSSION
The data that we present here suggest that the SASP is not a singular entity, but a complex evolving entity with tightly regulated composition and spatial activity, dependent on the level of NOTCH activity. We provide evidence for an additional layer of non-autonomous activity of senescence: 'lateral induction' , which was originally described in NOTCH-mediated control of boundary formation during embryonic development 25 . Interestingly, recent studies have identified embryonic senescence as a mechanism for developmental patterning: these senescent cells are accompanied by upregulation of TGF-β signalling and subsequent immune clearance 42, 43 . Another transcription factor involved in embryonic development, GATA4, positively regulates the SASP in part through upregulation of IL-1α 44 and NOTCH signalling appears to have a negative impact on GATA4 45 . It would also be interesting to test whether GATA4 plays a role in NOTCH-mediated inhibition of the C/EBPβ-IL1a axis. Additional implications of our data include a possibility that constitutively active NOTCH signalling in tumour cells drives lateral induction of senescence in the stroma. Emerging evidence suggests the important role of bone marrow stroma in survival/maintenance of Tcell ALL, which is associated with activating mutations of NOTCH1 46 .
It would be important to test whether NOTCH signalling derived from T-ALL cells can induce a NIS-like phenotype in the bone marrow stromal cells, which might have a substantial impact on the T-ALL niche.
Finally, therapeutic elimination of senescent cells has been suggested to provide beneficial effects on tissue homeostasis or tumour suppression 7, 8, 47, 48 . Manipulation of NOTCH may provide a unique therapeutic opportunity for targeting senescent cells through modulation of senescence surveillance.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
Cell culture. IMR90 (ATCC), WI38 (ATCC) and ESF (embryonic skin fibroblast) 49 (a gift from J. Gil, Imperial College, UK) human diploid fibroblasts were cultured as previously described in DMEM/10% fetal calf serum (FCS) in a 5% O 2 /5% CO 2 atmosphere. hTERT-RPE1 cells (a telomerase-immortalized human retinal pigment epithelial cell line; ATCC) were grown in DMEM/F12/10% FCS in a 5% O 2 /5% CO 2 atmosphere. HACAT cells (ATCC) were cultured in DMEM/10% FCS in a 21% O 2 /5% CO 2 atmosphere. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. Cell identity was confirmed through STR genotyping. Regular testing was always negative for mycoplasma contamination.
The following drugs and inhibitors were used: 4-hydroxytamoxifen (4OHT) (Sigma); N -[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT) (Sigma); SB431542 (Tocris); A 83-01 (Tocris); GW788388 (Tocris); etoposide (Sigma); recombinant human TGF-β1 (Cell Signaling); recombinant human TGF-β2 (Peprotech); recombinant human TGF-β3 (Peprotech); tumour necrosis factor (TNF); recombinant IL-1α (both R&D systems).
Vectors. The following retroviral vectors were used in this study: pBabe-puro for HRAS G12V ; pWZLhygro for N1ICD-FLAG (residues 1758-2556 of human NOTCH1, as described previously 52 ), mRFP1; pLPC-puro for dnMAML1-mVenus (residues 12-74 of human MAML1), N1ICD-FLAG, mRFP1; pQCXIH-i for N1ICD-FLAG, N1ICD-FLAG-mVenus, C/EBPβ-LAP * , dnSMAD4-mVenus (residues 1-514 of human SMAD4, as described previously 24 ); pQCXIN-i for N1ICD-FLAG; pMSCV-miR30-puro for JAG1 shRNA (target sequences: no. 1, 5 -GCGTGACCTGTGATGACTAC T-3 ; and no. 4, 5 -GGTCTTTGAGCTCCCACTTCT-3 ).
The tetracycline-inducible retroviral vectors (pQCXIH-i and pQCXIN-i) were cloned using the following strategies. A third-generation tet-responsible element (TRE3G) and a constitutively expressed rtTA3 tet-transactivator cassette were PCR-amplified from pCLIIP-i 19 . These two fragments were assembled by overlapextension PCR and the product was cloned into pQCXIH or pQCXIN (Clontech).
Plasmids for hydrodynamic tail-vein injection: pPGK-SB13; pT/CAGGS for NRAS G12V , NRAS G12V/D38A (ref.
8), NRAS G12V -IRES-mVenus, NRAS G12V -IRESdnMAML1-mVenus, NRAS
G12V -IRES-N1ICD-FLAG. Plasma membrane proteomics. PMP was performed as described previously 14 . Briefly, surface sialic acid residues were oxidized, biotinylated with aminooxybiotin (Biotium), and biotinylated cells incubated in a 1% Triton X-100 lysis buffer. Biotinylated glycoproteins were enriched with high-affinity streptavidin agarose beads (Pierce) and washed extensively. Captured protein was reduced, alkylated and then digested with trypsin on-bead overnight. Tryptic peptides were collected and fractionated. Glycopeptides were eluted using PNGase (New England Biolabs).
High-pH reverse-phase high-pressure liquid chromatography was performed on tryptic peptides as described previously 14 . LC-MS/MS was performed using a NanoAcquity uPLC (Waters) coupled to an LTQ-OrbiTrap XL (Thermo). Raw MS files were processed using MaxQuant version 1.3.0.5 (ref. 53) . Reversed decoy databases were used and the false discovery rates for both peptides and proteins were set at 0.01. Protein quantitation used razor and unique peptides and required a minimum of 2 ratio counts, with normalized protein ratios reported. Significance B values were calculated. We assessed the number of PM proteins identified as described previously 14 .
Proteomic analysis. Proteins were selected for differential expression analysis such that they had been quantified in at least two replicates, and that at least one of these quantifications was based on more than one peptide. A single-sample t-test was then applied to the mean log 2 fold change values to assess whether these were significantly different to zero. Proteins were selected as significantly differentially expressed if P value <0.05. All detected proteins were used for enrichment testing of GO localization (Cellular Component) terms using Metacore (Thomson Reuters). 'High confidence' was defined as follows: peptides identified in at least 2 independent replicates with at least 1 replicate having 2 or more peptides. Multiple testing correction was applied using the BenjaminiHochberg method. Genes were selected as differentially expressed with a false discovery rate of <0.01. Secretome genes were defined as previously described 56 .
Network analysis of proteomic and transcriptomic data. RIS-associated PMP data complemented by mRNA-Seq expression data were used to identify key senescenceassociated membrane protein network hubs. Proteins detected through PMP were merged with genes, but genes annotated in the cellular membrane compartment were excluded. Log 2 fold ratios were used for both proteomics and transcriptomic data. Data were analysed using Ingenuity Pathway Analysis (IPA) (QIAGEN); the possible interaction networks were generated using Ingenuity knowledge base and included only direct relationships. Default settings were used, apart from restricting the networks to experimentally observed interactions in human data. The highest scoring network as assigned by IPA, presented here, highlighted the importance of NOTCH1 as a key hub in the PMP data. For graph readability we removed interactions from non-hub genes.
Chromatin isolation.
Chromatin isolation was performed as described previously 50 .
BrdU incorporation, colony formation and SA-β-gal assays. Cellular proliferation by BrdU incorporation, colony formation and SA-β-gal analysis have been described previously 50 .
Cellular proliferation by Incucyte. Analysis of short-term cellular proliferation was performed in either an Incucyte-HD or Incucyte-Zoom device (Essen Bioscience) in a 21% O 2 atmosphere. Cells were plated, at 4 × 10 5 cells for monoculture or at 3.5 × 10 5 signal-sending cells with 1.5 × 10 5 target cells, in a 12-well plate in 1 ml cell culture media. Cell proliferation was determined through repeated measures of confluency on phase or epifluorescent imaging.
Gene set enrichment analyses (GSEA)
. GSEA were performed as described previously 57 . P values derived from DESeq analyses of the RNA-Seq data were − log 10 transformed and then signed according to whether genes were up(+)-or down(−)-regulated compared with control samples. These values were then used for ranking and weighting of genes in subsequent GSEA analyses 58 . Cell-cycle-related gene sets were obtained from the Molecular Signatures Database (http://software. broadinstitute.org/gsea/msigdb). Other gene signatures used were obtained from data sets in the Gene Expression Omnibus (GEO). Supplementary Fig. 9 , including molecular weight markers.
Protein from conditioned media was obtained by plating 2.5 × 10 6 cells in media with 2% FCS for 16 h before filtration through a 0.22 µm filter and then centrifugation at 4,000g for 20 minutes through a Vivaspin 6 concentrator column (10 kDa molecular weight cutoff, GE Healthcare). Coomassie staining of gels was performed as previously reported 50 .
Hydrodynamic tail-vein injection. All animal experiments were approved by the German or UK legal authorities, and mice were kept under pathogen-free conditions in accordance with the institutional guidelines of the University of Tuebingen or University of Cambridge. Male and female C57BL/6 mice were purchased from Charles River and injected at 5-8 weeks of age. Vectors for hydrodynamic injection were prepared with the Qiagen EndoFree MaxiPrep kit. Transposon-mediated gene transfer was previously described 8 ; briefly 20 µg of appropriate vector and 5 µg of SB13 transposasecontaining plasmid were diluted in sterile-filtered phosphate-buffered saline to a total volume of 10% of the body weight of the animal before being injected into the lateral tail vein in under 10 s.
Immunohistochemistry. Formalin-fixed paraffin-embedded mouse tissues were stained with the following antibodies: anti-Notch1 (Cell Signaling, 3608, 1:200); anti-Dec1 (a gift from A. Harris, 1:2,000); anti-NRAS (Santa Cruz, sc-31, 1:100); anti-Hes1 (Cell Signaling, 11988, 1:250); anti-p21 (BD, 556431, 1:50); anti-CD3 (Dako, A0452, 1:1,000); anti-B220 (R&D systems, MAB1217, 1:1,500); anti-Ki-67 (Bethyl, IHC-00375, 1:1,000); anti-cleaved caspase 3 (Cell Signaling, 9664, 1:1,000) after heat-induced epitope retrieval in citrate (pH 6) or Tris-EDTA (pH 9) buffers before visualization using the DAKO Envision kit according to the manufacturer's instructions and counterstaining with haematoxylin. Dual chromogenic immunohistochemical staining was performed on a Leica Bond Max (Leica) using the polymer refine detection and refine red detection kits (Leica). For fluorescent labelling, we used anti-CD3 (as above) and anti-GFP (Abcam, ab13970, 1:100) with appropriate fluorochrome-tagged secondary antibodies (Life Technologies).
All slides were scanned on a Leica AT2 at ×20 magnification and a resolution of 0.5 µm per pixel. Following digitization, image analysis was performed using the HALO (Indicalabs), using the Cytonuclear v1.4 algorithm. Each stain was trained independently to provide the best accuracy for cell counting and all of the slides were reviewed manually following analysis to assess accuracy. NRAS staining was counted manually from 4 random high-power fields containing a median of 1,457 hepatocytes (range 1,304-1,678) as described previously 8 , due to problems segmenting individual cells when staining was very intense.
Isolation and culture of human liver sinusoidal endothelial cells (HSECs).
Tissue samples and blood samples from patients were obtained with written informed consent and with local ethics committee approval (LREC reference 06/Q2702/61, UK and 04/Q2708/41). Liver endothelial cells were isolated from explanted livers or donor tissue surplus to surgical requirements using a collagenase digestion (collagenase type 1a, Sigma-Aldrich) as described previously 60 . All tissue was collected from patients in the Liver Unit at Queen Elizabeth Hospital in Birmingham. Briefly, digested tissue was placed over a 33%/77% Percoll (Amersham Biosciences) density gradient. The endothelial cells were isolated by immunomagnetic selection using antibodies against CD31 conjugated to Dynabeads (Life Technologies). The endothelial cells were then cultured in medium composed of human endothelial basal growth medium (Life Technologies), 10% AB human serum (HD supplies), 10 ng ml −1 vascular endothelial growth factor (VEGF), and 10 ng ml −1 hepatocyte growth factor (HGF) (Peprotech). The cells were grown in collagen-coated culture flasks and were maintained at 37 • C in a humidified incubator with 5% CO 2 until confluent.
Isolation of peripheral blood lymphocytes (PBLs).
PBLs were isolated as previously described 61 by density gradient centrifugation over Lympholyte (VH Bio) at 800g for 25 minutes. Harvested lymphocytes were re-suspended in RPMI 1640 (Life Technologies)/10% FCS.
Flow adhesion assay.
To study immune cell recruitment, HSECs were grown in Ibidi µ-slide IV flow channels (Thistle Scientific) until confluent. HSECs were then cultured in conditioned media for 24 h before connection to the flow system previously described 35 . Peripheral blood lymphocytes were perfused through the microslides over the endothelial cells at a shear stress of 0.05 Pa. Phase-contrast video recordings made during lymphocyte perfusion were analysed offline to determine adherence. Adherence is expressed as numbers of adherent cells per square millimetre per million perfused cells (cells per mm 2 per 10 6 ).
Analysis of the IL1A locus. All sequence data were obtained from IMR90 cells. IL1A is shown with both the hg19 RefSeq annotation 62 , and GenCode version 19 annotation 63 . C/EBPβ ChIP-Seq and DNAase-Seq data are from the Encode Project 39 , and Histone data are from the Roadmap Epigenomics Project 40 . The data were visualized using the Gviz Bioconductor library.
Chromatin immunoprecipitation (ChIP)
. ChIP was performed as described previously 64 with modifications. Briefly, 50 µg of chromatin and 10 µg of antibody (C/EBPβ: Santa Cruz sc-150) were applied to each IP. For the negative control no antibody was added to the IP. Three replicate ChIPs were carried out for each condition followed by qPCR. Primer sequences used in qPCR are as follows:
IL6 ( The primer sets for IL6 and IL8 were previously reported 6 . For IL1A 'Proximal' (promoter) and 'Distal' (enhancer), qPCR primers were designed on the basis of C/EBPβ ChIP-seq data (ENCODE). In this case, 'nonspecific' is upstream of the IL1A promoter. The locations of the primer sets for IL1A are illustrated in Supplementary  Fig. 8e .
Statistics and reproducibility.
No statistical method was used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments. Unless otherwise stated, data are presented as the mean ± s.e.m. n values represent the number of independent experiments performed or the number of individual mice per condition. For each independent in vitro experiment a minimum number of three experiments were performed to ensure reproducibility and adequate statistical power. For in vivo experiments all conclusions were based on a minimum of three mice per condition or time point. Analyses were conducted using Graphpad Prism 6. Student's t-test was used for twocondition comparisons; one-way ANOVA with Dunnett's multiple comparison test for more than two conditions. In the statistical analyses, two-tailed tests were used throughout; a P value of 0.05 was taken as significant. All of the study data including statistical tests and exact P values are provided in Supplementary Table 2 .
Data availability. The RNA-Sequencing data generated for this study have been deposited at the Gene Expression Omnibus (GEO) with the accession numbers GSE72404, GSE72407 and GSE72409. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 82 partner repository with the data set identifier PXD004168.
The TGF-β1 signature was derived from previously published data available from GEO under accession codes GSE12493 (ref. 65) and GSE29660 (ref. 66) . The C/EBPβ signature was derived from previously published data available from GEO under accession codes GSE47777 and GSE30834 37 . Chromatin immunoprecipitation data sets were obtained from GEO with the following accessions: C/EBPβ, GEO ID GSM935519; DNase-Seq, GEO ID GSM1008586; H3K27ac, GEO ID GSM469966; H3K4me1, GEO ID GSM521895; H3K4me3, GEO ID GSM521901.
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